New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
09:31 EDTISISIsis Pharmaceuticals reports final Phase 2 data on ISIS-APOCIII Rx
Isis Pharmaceuticals announced the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIIIRx achieved average reductions of up to 71% in apolipoprotein C-III and up to 64% in triglycerides, and average increases of up to 52% in high-density lipoprotein cholesterol, the 'good' cholesterol. While the starting average triglyceride level in the 300 mg group was 384 mg/dL, 70% of these patients reduced their triglyceride level to below the normal level of 150 mg/dL. In addition, lipoprotein particle analysis showed significant dose-dependent reductions in the number of very low-density lipoprotein particles and significant increases in the number of HDL particles.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
18:04 EDTISISIsis Pharma granted FDA orphan status for treatment of familial chylomicronemia
Subscribe for More Information
08:58 EDTISISIsis Pharmaceuticals shares not reflecting SMA data, says Needham
Subscribe for More Information
June 22, 2015
07:01 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx in Phase 2 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use